New cocktail of drugs aims to keep HER2+ breast cancer in check

NCT ID NCT07610720

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial is testing whether adding the drug dalpiciclib to standard anti-HER2 and hormone therapy can help keep advanced breast cancer from growing. It involves 57 women with HR+/HER2+ metastatic breast cancer whose disease has not worsened after initial treatment. The study measures how long participants live without their cancer progressing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dalpiciclib (a CDK4/6 inhibitor) combined with trastuzumab, pertuzumab, pyrotinib, and endocrine therapy (letrozole, anastrozole, exemestane, or fulvestrant)
What this could lead to: If successful, this could offer a new first-line maintenance treatment option to delay cancer progression in people with HR+/HER2+ metastatic breast cancer.
What could go wrong: This is a small Phase 2 trial with only 57 participants, so results may not apply to everyone. Side effects from the drug combination, such as diarrhea, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma triple-positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED/METASTATIC BREAST CANCER HER2-POSITIVE METASTATIC BREAST CANCER

Contacts and locations

Locations

Sun yat-Sen University Cancer Center, Guangzhou, Yuexiu District
RECRUITING

Guangdong, GUANGZHOU, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.